The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.oa1474
Abstract: Introduction: Squamous cell carcinoma (SCC) accounts for 20-30% of lung cancer cases but new treatment options are limited. Retrospective subgroup analyses showed nab-paclitaxel (nab-P) plus carboplatin produced a significantly higher overall response rate (41%) than… read more here.
Keywords: carboplatin patients; treatment; safety; efficacy ... See more keywords
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.02404
Abstract: PURPOSE Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin. PATIENTS… read more here.
Keywords: response; monotherapy; atr inhibitor; carboplatin patients ... See more keywords